Benchtalk Boston 2025 Event Brief Benchling hosted over 500 participants – including customers, partners, prospects and analysts at Benchtalk 2025 Boston, its annual industry event showcasing […]
Spanning Research, Development and GxP-Regulated Environments Read More »
Tulip Operations Calling 2025 Event Brief Tulip’s third annual Operations Calling event drew over 600 attendees to Somerville, MA — the company’s largest and most energetic
Continuous Transformation on the Frontline Read More »
Highbyte DataOps Days Boston Event Brief HighByte hosted its third of three 2025 U.S. DataOps Days at The Engine in Cambridge, MA, gathering roughly 45
Industrial DataOps: The Backbone of AI-Ready Manufacturing Data Read More »
Sapio Sciences Briefing Note Axendia was recently briefed by Mike Hampton, Chief Commercial Officer, and Rob Brown, VP and Head of the Scientific Office, at Sapio Sciences.
Sapio Introduces The Electronic Notebook That Thinks Like A Scientist Read More »
The FDA’s remote regulatory assessments (RRAs) are no longer temporary pandemic measures. Over the past few years, the agency has made it clear that it
Is Your Lab Ready for the FDA’s Remote Data Access Era? Read More »
Axendia’s Event Brief of Benchling Development Summit The 2025 Benchling Development Summit, held in June 2025, brought together over 40 senior biopharma leaders at the
How Biopharma is Digitally Transforming to Accelerate Development Read More »
HighByte Briefing Note Axendia was briefed by Torey Penrod-Cambra, Co-Founder & Chief Communications Officer, and Jeffrey Schroeder, Product Manager, at HighByte, a software company that was founded in
Moving Data with Purpose to Drive Value Read More »
ETQ Briefing Note Axendia was recently briefed by the executive team at ETQ, part of Hexagon, including Chris Nahil, Analyst Relations, Maureen Pienta, CMO and
Empowering Quality-Driven Innovation Read More »
The FDA has taken another step towards realizing their vision for encouraging pharmaceutical quality management practices. FDA’s Center for Drug Evaluation and Research (CDER) has developed
FDA Encourages Industry to Achieve Quality Management Maturity (QMM) Read More »
FDA’s Center for Drug Evaluation and Research (CDER) recently released its fifth annual report on the State of Pharmaceutical Quality. It reviews the state of
FDA Reports on the State of Pharmaceutical Quality Read More »
The Inflation Reduction Act (IRA) will drive a significant change in the pharmaceutical industry, empowering Medicare to negotiate the prices of high-cost single-source brand-name drugs
Price Negotiations: 10 Initiatives Pharma Must Consider To Mitigate Impacts Read More »
